Move over Ozempic, your 15 minutes of fame is fading fast, as evidenced by presentations at the
American Diabetes Association meeting in San Diego. "The drug will still be widely
used, but a bewildering array of medications for obesity is advancing through development, and in the coming years, they will become a bewildering array of options for patients," per The
Atlantic, including a compound called retatrutide which
is perhaps the best of all
, with effects approaching those of bariatric
surgery.Read the whole story at The Atlantic »
